会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Method for down-regulating GDF-8 activity
    • 降低GDF-8活性的方法
    • US07056512B1
    • 2006-06-06
    • US09620586
    • 2000-07-20
    • Steen KlysnerSoren MouritsenTorben Halkier
    • Steen KlysnerSoren MouritsenTorben Halkier
    • A61K39/00A61K39/38
    • C07K14/475A61K38/00A61K39/00A61K39/0005A61K48/00A61K2039/523A61K2039/53A61K2039/55516A61K2039/55522C07K2319/00
    • Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
    • 公开了通过免疫接种生长分化因子8(GDF-8,肌生成抑制素)来增加肌肉质量的新方法。 免疫优选通过施用能够诱导针对同源GDF-8的抗体产生的GDF-8的类似物来实现。 特别优选的是作为免疫原的同源GDF-8,其通过引入一个或多个外来的免疫显性和混杂的T细胞表位而被修饰,同时基本上保留了同源的GDF-8的三级结构。 还公开了针对GDF-8的核酸疫苗接种和使用活疫苗的疫苗接种以及用于疫苗接种的方法和装置。 这些方法和手段包括鉴定有用的免疫原性GDF-8类似物的方法,制备类似物和药物制剂的方法,以及核酸片段,载体,转化细胞,多肽和药物制剂。
    • 4. 发明申请
    • Method for down-regulating IgE
    • IgE下调方法
    • US20020172673A1
    • 2002-11-21
    • US09949375
    • 2001-09-06
    • Pharmexa A/S
    • Steen KlysnerPaul von HoegenBjorn VoldborgAnand Gautam
    • A61K039/395
    • A61K39/0008A61K2039/6037
    • The present invention discloses methods for immunizing against autologous (self) Immunoglobulin E (IgE). In particular, the invention discloses methods for inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination. Also disclosed are methods for inducing antibodies reactive with autologous IgE as well as methods for inducing a combined antibody and CTK response specific for IgE. The invention also discloses specific immunogenic protein constructs, nucleic acids encoding these as well as various formulations and tools for preparing the vaccines, including vectors and transformed host cells.
    • 本发明公开了免疫自体免疫球蛋白E(IgE)免疫的方法。 特别地,本发明公开了诱导细胞毒性T淋巴细胞的方法,其特别是通过核酸接种或活疫苗接种来特异性地下调产生自体IgE的B细胞。 还公开了诱导与自体IgE反应的抗体的方法以及用于诱导IgE特异性的组合抗体和CTK应答的方法。 本发明还公开了特异性免疫原性蛋白质构建体,编码这些蛋白质的核酸以及用于制备疫苗的各种制剂和工具,包括载体和转化的宿主细胞。
    • 7. 发明申请
    • Method for identification of biologically active peptides and nucleic acids
    • 鉴定生物活性肽和核酸的方法
    • US20030082514A1
    • 2003-05-01
    • US10178045
    • 2002-06-20
    • Pharmexa A/S
    • Martin Roland JensenFinn Skou PedersenSoren MouritsenPeter HinderssonMogens DuchMichael Schandorf SorensenIben DalumAnders Henrik Lund
    • C12Q001/00C12Q001/68C12P019/34C12N015/85
    • C40B30/04C12N15/1034C12Q1/6811G01N33/5005G01N33/6845
    • Biologically active peptides and nucleic acids are identified by a method comprising the following steps: (a) production of a pool of appropriate vectors each containing totally or partly random DNA sequences, (b) efficient transduction of said vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell, (c) screening of said transduced cells to see whether some of them have changed a certain phenotypic trait, (d) selection and cloning of said changed cells, (e) isolation and sequencing of the vector DNA in said phenotypically changed cells, and (f) deducing the ribonucleic acid and peptide sequences from the DNA sequence. The peptide sequences may be introduced into or fused to a larger protein, preferably an antibody molecule or a fragment thereof. This may be obtained by introducing the random DNA sequences into or fusing them to a DNA sequence encoding such larger protein.
    • 通过包括以下步骤的方法鉴定生物活性肽和核酸:(a)制备各自含有完全或部分随机DNA序列的合适载体池,(b)将所述载体有效转导到多个相同的真核细胞中 以这样一种方式,单个核糖核酸和可能的肽被表达,或者有限数目的不同的随机核糖核酸和肽被每个细胞表达,(c)筛选所述转导的细胞,看看它们中有些是否已经改变了某种表型 特征,(d)所述改变的细胞的选择和克隆,(e)在所述表型改变的细胞中分离和测序载体DNA,和(f)从DNA序列推导核糖核酸和肽序列。 肽序列可以被引入或融合到较大的蛋白质,优选抗体分子或其片段中。 这可以通过将随机DNA序列引入或将其融合到编码这种较大蛋白质的DNA序列而获得。